architecturesmakesitdifficulttoascertainwhatparametersmay ormaynotinfluencetheactivitiesoftheTALEactivatorstested inthesepreviousstudies(Supplementary Table 1) .
Hereweleveragedourrecentlydevelopedfastligation-based automatable solid-phase high-throughput (FLASH) assembly method 12 to systematically test the activities of TALE activators.Ininitialexperiments,weconstructedmanyTALEactivatorscomposedofvariablenumbersofTALErepeatsandtested thecapabilitiesoftheseactivatorstostimulateexpressionofthe endogenoushumanVEGFAgene.Wetargetednineregionsin a DNase I hypersensitive site located~500 base pairs downstreamoftheVEGFAtranscriptionstartsite( Fig. 1a) artificial activators designed using transcription activator-like effector (taLe) technology have broad utility, but previous studies suggest that these monomeric proteins often exhibit low activities. here we demonstrate that taLe activators can robustly function individually or in synergistic combinations to increase expression of endogenous human genes over wide dynamic ranges. these findings will encourage applications of taLe activators for research and therapy, and guide design of monomeric taLe-based fusion proteins.
RapidadvancesinXanthomonassp.-derivedTALEtechnologyhave enabledanyresearchertoconstructcustomizableDNA-binding domainswithbroadpotentialusesfortargetedalterationofgene sequence or expression. Highly conserved 33-35-amino-acid TALErepeatdomainseachbindonenucleotideofDNAwithspecificitydictatedbytwohypervariableresidues 1 .Thisone-to-one codeallowsonetodesignproteinswithdesiredDNA-bindingspecificitiesbysimplyjoiningTALErepeatsintoanarray.Recently, considerableefforthasbeenfocusedondimericTALEnucleases (TALENs), artificial proteins composed of customized TALE repeatsfusedtoanucleasedomain,whichenabletargetedmodificationofendogenousgenesinavarietyoforganismsandcell types 1, 2 .EngineeredTALEshavealsobeenfusedtoheterologous transcriptionalactivationdomainstoconstructartificialmonomericTALEactivators [3] [4] [5] [6] [7] [8] [9] [10] [11] (Supplementary Fig. 1 Fig. 2andOnlineMethods) . Notably,allsixTALEactivatorstargetedtotheVEGFApromoter and four of five TALE activators targeted to the miR-302/367 promoterinducedsignificantincreasesintargetgeneexpression in human HEK293 and primary BJ fibroblasts, respectively (Fig. 2a,b) .BecauseNTF3mRNAwasexpressedatanessentially undetectablelevelintheHEK293cellsusedforourexperiments, wecouldnotquantifyfold-activationvaluesforproteinstargeted tothisgene,butallfiveTALEactivatorssignificantlyincreased expressionofNTF3relativetoaGAPDHcontrol (Fig. 2c) .Overall, 15of16TALEactivators(~94%)inducedsignificantincreasesin expressionoftheirendogenousgenetargets( Fig. 2a-c) .
WenextexploredwhetherreplacingtheVP64domaininour TALEactivatorswithanNF-κBp65domainwouldleadtocon-sistentlyhigherorlowertargetgeneexpression.Forthe15target sitesforwhichweobtainedactiveTALEactivators,themeanfold activation induced was lower with the NF-κB p65-containing TALEactivatorsthanwiththeirmatchedVP64-containingcounterparts(herecalledp65andVP64TALEactivators,respectively; Fig. 2a-c) . We conclude that substitution with an NF-κB p65 domaincanprovideageneralapproachforreducingtheactivationinducedbyTALEactivatorsbearingaVP64domain.
BecausewegeneratedmorethanoneactiveTALEactivatorfor eachtargetgene,wealsotestedwhethermultipleproteinsworking simultaneouslyonasinglepromotercouldinduceevengreater activation. Naturally occurring transcriptional activators can exhibitsynergy:thatis,theactivationobservedinthepresence ofmultipleproteinsishigherthantheadditiveeffectsoftheindividualproteins 14 .Activatorsynergyenablesbothcombinatorial andgradedcontroloftranscriptionineukaryotes.WetestedcombinationsoffiveVP64orp65TALEactivatorsfortheirabilities toactivatethemiR-302/267clusterortheNTF3gene.Despitethe factthateachTALEactivatorplasmidwaspresentatone-fifththe amountusedwhentestedindividually,wefoundthattransfection withmultipleplasmidseachencodingadifferentTALEactivator inducedsubstantiallyelevatedtargetgeneexpression (Fig. 2b,c) . WeobservedsynergisticactivationwithVP64andp65TALEacti-vatorsonthemiR-302/367clusterandwithp65activatorsonthe NTF3gene (Fig. 2b,c) .WealsotestedcombinationsofsixVP64or p65TALEactivatorsfortheirabilitiestoactivatetheVEGFAgene butdidnotobservesynergisticincreasesinexpression(datanot shown).Wehypothesizedthatthelackofobservedsynergymight be due to the different amounts of TALE activator-encoding plasmidsusedintheindividualandcombinationexperiments. Consistentwiththis,wefoundthatboththeVP64andp65TALE activatorsmediatedsynergisticincreasesinVEGF-Aexpression underconditionswherethesameamountsofactivatorplasmids wereusedwhentestedindividuallyorincombinations (Fig. 2d) . WeconcludethatbothVP64andp65TALEactivatorscanfunc-tion synergistically to induce even greater endogenous gene expressionthancanbeachievedusingindividualactivators.
Our ability to robustly construct highly active TALE activatorscontrastswiththecollectiveresultsofpreviousstudies that described proteins with often much lower activities on endogenousgenetargets. 
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Cell culture and transfection.HumanFlp-InT-RExHEK293cells andprimaryhumanBJfibroblastsweremaintainedinAdvanced DMEMsupplementedwith10%FBS,1%penicillin-streptomycin and1%Glutamax(LifeTechnologies).Cellsweretransfectedusing eitherLipofectamineLTX(LifeTechnologies)orNucleofectortechnology(Lonza)accordingtomanufacturer'sinstructions.Briefly, for experiments targeting VEGFA and NTF3, 160,000 Flp-In T-RExHEK293cellswereseededin24-wellplatesandtransfected thefollowingdaywith300ngofplasmidencodingtheTALEacti-vator(exceptinthereduced-concentrationVEGF-Aexperiments (Fig. 2d) inwhich50ngofplasmidencodingTALEactivatorand 250ngofacontrolplasmidexpressingonlytheactivationdomain weretransfected),30ngofpmaxGFPplasmid(Lonza),0.5µlPlus Reagentand1.65µlLipofectamineLTX.ForthesynergyexperimentswithVEGFAandNTF3,wetransfectedcellswith300ng ofTALEactivator-encodingplasmids(50ngofeachofsixTALE activator-encodingplasmidsforVEGFAand60ngofeachoffive TALEactivator-encodingplasmidsforNTF3).ForexperimentstargetingmiR-302/367clusterexpression,5×10 5 BJfibroblastswere transfectedusingNucleofectortechnologywith10µgofplasmid encodingTALEactivatorand500ngofpmaxGFPplasmidusing theNHDFkit(Lonza)andprogramU-023ontheNucleofector2b device.ForthesynergyexperimentwithmiR-302/367,wetransfectedcellswith10µgofTALEactivator-encodingplasmids(2µg ofeachoffiveTALEactivator-encodingplasmids).
Enzyme-linked immunosorbent assays.Flp-InTRExHEK293 cells were transfected with plasmids encoding TALE activatorstargetedtothehumanVEGFAgene.Alltransfectionswere performed in triplicate. Cell medium was collected 40 h after transfection,andsecretedVEGF-Aproteinlevelsinthemedium wereassayedusingaHumanVEGF-AELISAkit(R&DSystems). All samples were measured according to the manufacturer's instructions. Fold-activation values were calculated by dividing mean VEGF-A amounts in medium collected from cells transfectedwithplasmidsexpressingTALEactivatorsbymean VEGF-Aamountsinmediumfromcellstransfectedwithplasmid expressingonlytheVP64orNF-κBp65activationdomain.
Quantitative reverse transcription-PCR assays. To measure NTF3 mRNA levels, cells were collected 2 d after transfection, and total RNA was isolated using the TRIzol Plus RNA purification system (Ambion). RNA was reverse-transcribed using SuperScript III First-Strand Synthesis SuperMix and oligo(dT) primer (Life Technologies). Quantitative PCR was then performed using the following Taqman primer/probe sets,aspreviouslydescribed 3 exceptwiththemodificationthat the GAPDH probe was labeled with a 5′ hexachlorofluorescein (HEX) fluorophore to allow for multiplexing. NTF3 forward primer: 5′-GATAAACACTGGAACTCTCAGTGCAA-3′; NTF3reverseprimer:5′-GCCAGCCCACGAGTTTATTGT-3′; NTF3 Taqman probe: 5′-/56-FAM/CAAACCTAC/ZEN/ GTCCGAGCACTGACTTCAGA/3IABkFQ/-3′;GAPDHforward primer:5′-CCATGTTCGTCATGGGTGTGA-3′;GAPDHreverse primer:5′-CATGGACTGTGGTCATGAGT-3′;GAPDHTaqman probe:5′-/5HEX/TCCTGCACC/ZEN/ACCAACTGCTTAGCA/ 3IABkFQ/-3′.AllTALEactivator-encodingplasmidsandcontrol plasmids were introduced into cells by transfection using Nucleofector technology in triplicate and quantitative reverse transcription-PCR (RT-PCR) was performed in triplicate on eachsample.
To measure miR-302a transcript levels, cells were collected 3 d after transfection and GFP-positive cells were isolated by flow cytometry. Total microRNA was isolated using the mirVanamiRNAIsolationkit(Ambion).Reversetranscription andquantitativePCRwereperformedaccordingtomanufacturer's instructionsusingAppliedBiosystemsTaqmanmicroRNAassays (#000529 for has-miR-302a and #001006 for RNU48 control). FoldactivationofmiR-302aRNAtranscriptswascalculatedby comparingtranscriptamountsinBJfibroblaststransfectedwith plasmidsencodingTALEactivatorstotranscriptamountsinBJ fibroblaststransfectedwithcontrolplasmidsexpressingonlythe VP64orNF-κBp65activationdomainsandusingthecompara-tivecyclethreshold(∆∆Ct)method.AllTALEactivatorsandcontrolswereintroducedintocellsbytransfectionusingNucleofector technology,intriplicate,andquantitativeRT-PCRformiR302a transcript and small RNA control SNORD48 (RNU48) were performedintriplicateoneachsample.
